Biologically active complex

Details Biologically active complex Biologically active complex

2009-12-07

2011-11-01

Gonzalez, Porfirio Nazario (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heavy metal containing doai

C514S706000

Reexamination Certificate

active

08048915

ABSTRACT:
The invention relates to an aqueous solution containing at least one species selected from the group consisting of a 1:1 molar complex of TeO2with a moiety of formula (A) and ammonium salts thereof:in-line-formulae description="In-line Formulae" end="lead"?HO—X—OH   (A)in-line-formulae description="In-line Formulae" end="tail"?where X is an optionally substituted divalent saturated hydrocarbon group containing 2-8 carbon atoms in the chain connecting the two OH groups; and its use for stimulating cells to produce cytokines and for treating mammalian diseases and conditions responsive to increased production of cytokines. The complex may be used also for treating mammalian cancer which is not responsive to increased production of cytokines.

REFERENCES:
patent: 4752614 (1988-06-01), Albeck et al.
patent: 4761490 (1988-08-01), Albeck et al.
patent: 4929739 (1990-05-01), Sredni et al.
patent: 5093135 (1992-03-01), Albeck et al.
patent: 6245330 (2001-06-01), Horellou et al.
patent: 7276628 (2007-10-01), Albeck et al.
patent: 2005/0004091 (2005-01-01), Albeck et al.
patent: 2009/0054391 (2009-02-01), Albeck et al.
patent: 0194393 (1986-09-01), None
patent: 0333263 (1989-09-01), None
patent: WO9316993 (1993-09-01), None
patent: WO 03/044038 (2003-05-01), None
patent: WO03044038 (2003-05-01), None
patent: W02004110338 (2004-12-01), None
Communication Pursuant to Article 96(2) EPC Dated Aug. 3, 2007 From the European Patent Office Re.: Application No. 02779867.7.
Official Action Dated Nov. 9, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/496,729.
Communication Pursuant to Article 96(2) EPC Dated Jan. 12, 2007 From the European Patent Office Re.: Application No. 02779867.7.
Notice of Allowance Dated May 25, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/496,729.
Official Action Dated Aug. 5, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/898,290.
Official Action Dated Jul. 31, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/496,729.
Response Dated Dec. 7, 2009 to Official Action of Aug. 5, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/898,290.
Response Dated Feb. 7, 2008 to the Communication Pursuant to Article 96(2) EPC of Aug. 3, 2007 From the European Patent Office Re.: Application No. 02779867.7.
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Mar. 11, 2009 From the European Patent Office Re.: Application No. 02779867.7.
Supplementary Partial European Search Report Dated Jul. 11, 2005 From the European Search Report Re.: Application No. 02779867.7.
Albeck et al. “Synthesis and Properties of Ammonium Trichloro(Dioxyyethylene-0,0)Tellurate (AS-101). A New Immunomodulating Compound”, Synthesis, p. 635-636, 1989.
Albeck et al. “Tellurium Compounds: Selective Inhibiton of Cysteine Proteases and Model Reaction With Thiols”, Inorganic Chemistry, 37(8): 1704-1712, 1998. p. 1705, col. 1, Lines 17-20.
Denney et al. “Preparation and NMR Studies of Tetraalkoxyselenuranes and Tetraalkoxytelluranes”, Journal of the American Chemical Society, 103(9): 2340-2347, 1981.
Gillis et al. “T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity”, The Journal of Immunology, 120(6): 2027-2032, 1978.
Lima et al. “A Novel Organotellurium Compound (RT-01) as a New Antileishmanial Agent”, Korean Journal of Parasitology, 47(3): 213-218, Sep. 2009.
Mbabazi “Sugar Complexes on Sn(IV), Sb(V), and Te(VI) Hydroxyanions”, Carbohydrate Research, 140: 151-154, 1985.
Persike et al. “Protective Effect of the Organotelluroxetane RF-07 in Pilocarpine-Induced Status Epilepticus”, Neurobiology of Disease, 31: 120-126, 2008.
Pietra et al. “The Effects of Carcinogenic Chemicals in Newborn Mice”, Cancer, 14(2): 308-317, 1961.
Uchiyama et al. “A Monoclonal Antibody (Anti-Tac) Reactive With Activated and Functionally Mature Human T Cells. II. Expression of Tac Antigen on Activated Cytotoxic Killer T Cells, Suppressor Cells, and on One of Two Types of Helper T Cells”, The Journal of Immuno logy, 126(4): 1398-1403, 1981.
Notice of Allowance Dated Mar. 5, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/898,290.
Office Action Dated Feb. 3, 2010 From the Israel Patent Office Re.: Application No. 146694 and Its Translation Into English.
Makarovsky D et al I“Tellurium compound AS101 includes PC12 differentiation and rescues the neurons from apoptotic death” Annals of the New York Academy of Sciences,Dec. 2003 LNKD-PUBMED: 15033807, vol. 1010, Dec. 1, 2003, pp. 659-666.
Geffen R et al:“A novel treatment for Parkinson's disease using an immunomodulator” Abstract of the Annual Meeting Society for Neuroscience, 30th Annual Meeting Society for Neuroscience, New Orleans, LA, USA.Nov. 4-9, 2000, Society for Neuroscience, Washington, DC, US, vol. 26, No. 1-2, Jan. 1, 2000, p. 1.
Kurkowska-Jastrzebska I et al: “Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice” International Immunopharmacology, vol. 2, No. 8, Jul. 2002, pp. 1213-1218.

Affiliated with

Also associated with

Rating

Biologically active complex does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biologically active complex, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active complex will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4295410